Exelixis
EXEL
#1695
Rank
HK$76.97 B
Marketcap
HK$269.53
Share price
-3.83%
Change (1 day)
48.00%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2023 (TTM): HK$2.22

According to Exelixis's latest financial reports the company's current EPS (TTM) is HK$2.20. In 2022 the company made an earnings per share (EPS) of HK$4.43 a decrease over its 2021 EPS that were of HK$5.75.

EPS history for Exelixis from 2000 to 2023

Annual EPS

Year EPS Change
2023 (TTM)HK$2.22-49.77%
2022HK$4.43-22.97%
2021HK$5.75100%
2020HK$2.87-65.09%
2019HK$8.24-53.91%
2018HK$17.87333.96%
2017HK$4.12-260.61%
2016-HK$2.56-58.75%
2015-HK$6.22-42.45%
2014-HK$10.805.3%
2013-HK$10.2643.48%
2012-HK$7.15-264.29%
2011HK$4.35-165.88%
2010-HK$6.60-32.54%
2009-HK$9.79-17.65%
2008-HK$11.8975.86%
2007-HK$6.76-25.64%
2006-HK$9.098.33%
2005-HK$8.39-42.86%
2004-HK$14.6830.34%
2003-HK$11.27-5.23%
2002-HK$11.89-0.65%
2001-HK$11.97-51.88%
2000-HK$24.86

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
HK$27.20 1,135.69%๐Ÿ‡ฌ๐Ÿ‡ง UK
HK$24.71 1,022.57%๐Ÿ‡ซ๐Ÿ‡ท France
HK$14.15 543.02%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$30.85 1,301.34%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.94 4,894.71%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$109.44 4,871.87%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$14.45 556.55%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$77.70-3,629.83%๐Ÿ‡บ๐Ÿ‡ธ USA
-HK$6.53-396.51%๐Ÿ‡บ๐Ÿ‡ธ USA